We evaluated this concept by combining the PKM2 activator, TEPP-46, with the LDHA inhibitor, FX-11, and assessed efficacy in vitro and in vivo in preclinical models of pancreatic cancer. Here, LDHA is linked to pancreatic neoplasm.